Document |
Document Title |
WO/2014/194957A1 |
The present invention relates to new compounds according to formula (I). Said compounds are particularly useful for the improvement of organic electronic devices where the compounds according to the present invention are used e.g. as dop...
|
WO/2014/187262A1 |
Provided are a 2-phenyl-isoquinoline-1-ketone derivative having a structure of formula (I), and uses thereof. The compound has good inhibitory effect on Bruton's tyrosine kinase activity, and the median inhibition concentration of the co...
|
WO/2014/185856A1 |
The present invention relates to functionalized cyclic carbonates, urethanes and polyurethanes, their methods of production and uses thereof.
|
WO/2014/185739A1 |
The present invention relates to a novel acid dianhydride, a method for preparing the same, and a polyimide prepared therefrom. More specifically, the acid dianhydride according to the present invention is useful as a colorless transpare...
|
WO/2014/182688A1 |
The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the Mas receptor, and are useful in methods of treatment and alleviation of d...
|
WO/2014/178381A1 |
Provided is a new compound having glycogen synthase activation potency, but minimal activation of receptor PPAR, and a high degree of safety. A compound represented by general formula [I], or a pharmaceutically acceptable salt thereof....
|
WO/2014/173957A2 |
A compound of formula (I) wherein R is a C9-23 polyunsaturated alkenyl group; X is SO3R3, SO2R3, PO3R3, PO2R3, COCHal3, or COOR3; R1 and R2 are each independently H, a C1-6 a iky I group optionally substituted with OH, C6-10 aryl group o...
|
WO/2014/171272A1 |
Provided is a liquid crystal compound satisfying at least one physical property from among having excellent stability with respect to heat, light, or the like, a high clearing point, a low liquid-crystal-phase lower limit temperature, a ...
|
WO/2014/169711A1 |
The invention relates to 15-oxospiramilactone derivatives, specifically, the present invention relates to compounds as presented in formula I and formula II, isomers thereof, and solvates or pharmaceutically acceptable salts thereof. The...
|
WO/2014/169026A1 |
The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndr...
|
WO/2014/164167A1 |
Porphyrazines capable of localizing in a tumor of a mammal are disclosed. The porphyrazines are used in methods of imaging a tumor and in methods of treating tumors, either alone or in combination with a chemotherapeutic agent and/or rad...
|
WO/2014/165127A1 |
The present invention provides for compounds of formula (I) wherein R1, R2, R3, and R10 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of dis...
|
WO/2014/154682A1 |
The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine t...
|
WO/2014/157009A1 |
The purpose of the present invention is to provide a photoelectric conversion element which exhibits excellent responsivity and heat resistance. A photoelectric conversion element of the present invention is obtained by sequentially lami...
|
WO/2013/082345A9 |
The present invention provides compounds of Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (M...
|
WO/2014/153214A1 |
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using...
|
WO/2014/146553A1 |
The present invention belongs to the field of pharmaceutical chemistry, and, in particular, disclosed therein are a flavonoid derivative and use thereof. Disclosed is a flavonoid derivative having the structure of general formula (I) or ...
|
WO/2014/145713A2 |
This disclosure relates generally to aminoglycoside derivatives of Formula (I) as described herein. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating bacterial infection...
|
WO/2014/140081A1 |
This invention relates to bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and their use in methods of treatment and/or prev...
|
WO/2014/135355A1 |
The invention relates to an isononyl ester or isononyl ester mixture of an epoxidized fatty acid or an epoxidized fatty acid mixture, the fatty acid or fatty acid mixture being extracted from tall oil or linseed oil and the average numbe...
|
WO/2014/138302A1 |
A new class of antibiotics effective against methicillin-resistant Staphylococcus aureus (MRSA) is disclosed. Compounds of this class can impair cell-wall biosynthesis by binding to both the allosteric and the catalytic domains of penici...
|
WO/2014/135674A1 |
The present invention relates to substituted chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to R4, p and q are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NC...
|
WO/2014/128612A1 |
The invention relates to quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, Formula (I) wherein R1, R2, R3, R5, R6 and L are as defined in the description. Such compounds are s...
|
WO/2014/129701A1 |
Provided are a monomer for a hardmask composition which is represented by chemical formula 1, a hardmask composition comprising the monomer and a pattern forming method using the hardmask composition.
|
WO/2014/126070A1 |
Provided is a novel herbicide having a significant herbicidal activity on undesirable plants. A compound represented by general formula (I) [wherein R1 represents a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C3-6 cyc...
|
WO/2014/124220A1 |
Naturally-derived compounds having various structures elicit the perception of salty taste, enhance the perception of salty taste of a salt, or act at one or more sodium channels. Food products may include such naturally-derived compound...
|
WO/2014/122530A1 |
Embodiments of the present invention relate to 4-(phenoxymethyl)-1,3-dioxolane analogs and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the overproduction of Cortisol ...
|
WO/2014/124207A1 |
Naturally-derived compounds having various structures elicit the perception of salty taste, enhance the perception of salty taste of a salt, or act at one or more sodium channels. Food products may include such naturally-derived compound...
|
WO/2014/124191A1 |
Naturally-derived compounds having various structures elicit the perception of salty taste, enhance the perception of salty taste of a salt, or act at one or more sodium channels. Food products may include such naturally-derived compound...
|
WO/2014/124214A1 |
Naturally-derived compounds having various structures elicit the perception of salty taste, enhance the perception of salty taste of a salt, or act at one or more sodium channels. Food products may include such naturally-derived compound...
|
WO/2014/119892A1 |
The present disclosure relates to a novel method for preparing an arylnaphthalene lignan compound. In synthesis of arylnaphthalene lignan compounds and derivatives according to the present disclosure, a naphthalene backbone may be constr...
|
WO/2014/116669A1 |
Epoxy containing phosphonate monomers, polymers, copolymers, oligomers and co-oligomers and methods for making the same are describes herein. These materials can be used to make polymers, and can be combined with other polymers, oligomer...
|
WO/2014/113427A2 |
The present invention is directed to irciniastatin analogues. Uses of these analogues also described.
|
WO/2014/108011A1 |
The present invention relates to important intermediate 2 of entecavir and a method for preparing entecavir intermediate compound 1 through ring-closing reaction of compound 2 under the condition of free radicals with transition metals a...
|
WO/2014/104720A1 |
The present invention relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By using the organic electroluminescent compound according to the present invention, an organic electro...
|
WO/2014/094544A1 |
Provided are a phenyl C-glucoside derivative containing a deoxyglucose structure as represented by formula I, preparation method thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treati...
|
WO/2014/097041A1 |
This invention relates to compounds of general Formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds ...
|
WO/2014/098597A1 |
The invention relates to novel bis-chromone derivatives, methods for their preparation and their therapeutic application, especially in the treatment or prevention of disease involving mast cell activation, such as allergic disease. Prov...
|
WO/2014/100734A1 |
Described herein are compounds of formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compound...
|
WO/2014/088290A1 |
The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device comprising the same. Using the organic electroluminescent compound according to the present invention, an organic elect...
|
WO/2014/086712A1 |
The present invention relates to compounds of general formula I, wherein the groups (Het)Ar and R1 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activ...
|
WO/2014/086865A1 |
The present invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to 1-phenyl-2-pyridinyl alkyl alcohol derivatives, to processes for the preparation thereof, compositions comp...
|
WO/2014/086284A1 |
Disclosed in the invention are a deuterated 3-cyano quinoline compound or pharmaceutically acceptable salts, solvates, prodrugs, stereoisomers, tautomers, polymorphic substances, metabolites etc., and a pharmaceutical composition contain...
|
WO/2014/086894A1 |
The present invention relates to novel retinoid-related orphan receptor gamma (RORϒ) modulators and their use in the treatment of diseases mediated by RORϒ.
|
WO/2014/082889A1 |
Disclosed are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein X1, X2, X3, R1, R2 and R3 are as described in this application, methods for making said compounds as well as methods of using them in the treatmen...
|
WO/2014/084407A1 |
The present invention provides a compound having an excellent efficacy for controlling weeds. A dihydropyrone compound of formula (I): wherein m is 1, 2 or 3; n is an integer of any one of 1 to 5; X represents O, S, S(O) or S(O)2; R1 rep...
|
WO/2014/079803A1 |
The present invention relates to compounds of formula (la) or (lb) or pharmaceutically acceptable salts thereof for use in the treatment or prevention of hairloss, formula (Ia), (Ib) wherein Ra, Rb, Rc, Rd, Y1, Y2, Y3, Y4, Y5, Z, R1, R2,...
|
WO/2014/074675A1 |
Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, in...
|
WO/2014/071044A1 |
The invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R', R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are ...
|
WO/2014/065209A1 |
Provided are: a pyridine compound or a salt thereof that has excellent insecticidal activity and/or acaricidal activity, is highly safe, and can be synthesized industrially advantageously; and a pest control agent including the same as a...
|